![Nicholas Landekic](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nicholas Landekic
Vorstandsvorsitzender bei PolyMedix Pharmaceuticals, Inc.
Aktive Positionen von Nicholas Landekic
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PolyMedix Pharmaceuticals, Inc. | Vorstandsvorsitzender | 06.05.2011 | - |
Präsident | 06.05.2011 | - |
Karriereverlauf von Nicholas Landekic
Ehemalige bekannte Positionen von Nicholas Landekic
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
POLYMEDIX, INC. | Direktor/Vorstandsmitglied | 21.06.2011 | 30.01.2013 |
Gründer | 01.11.2005 | 30.01.2013 | |
Präsident | 01.11.2005 | 30.01.2013 | |
Locus Pharmaceuticals, Inc.
![]() Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Präsident | 01.01.2000 | 01.01.2002 |
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Public Communications Contact | 01.01.1995 | 01.01.2000 |
Cephalon, Inc.
![]() Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | 01.01.1991 | 01.01.1995 |
BRISTOL-MYERS SQUIBB COMPANY | Vertrieb & Marketing | 01.01.1988 | 01.01.1991 |
Ausbildung von Nicholas Landekic
Indiana University | Graduate Degree |
Marist College | Undergraduate Degree |
State University of New York at Albany | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
President | 3 |
Director/Board Member | 1 |
Founder | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private Unternehmen | 5 |
---|---|
PolyMedix, Inc.
![]() PolyMedix, Inc. Pharmaceuticals: MajorHealth Technology PolyMedix, Inc. engaged in developing first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company was founded in 2002 and was headquartered in Radnor, PA. | Health Technology |
Locus Pharmaceuticals, Inc.
![]() Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
Guilford Pharmaceuticals, Inc.
![]() Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Cephalon, Inc.
![]() Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
PolyMedix Pharmaceuticals, Inc. |
- Börse
- Insiders
- Nicholas Landekic
- Erfahrung